$NVLX - Comprehensive Analyst Report Answers Vit

$NVLX - Comprehensive Analyst Report Answers Vital Questions for Shareholders, by BrokerBank Securities, Inc.

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Nuvilex, Inc. (OTCQB: NVLX) owns exclusive rights to a cancer treatment platform that has successfully completed Phase 2 clinical trials for inoperable pancreatic cancer. Nuvilex also owns rights to the same platform to treat diabetes, and the company also has a medical marijuana subsidiary slated to begin cancer research and development using cannabidiol. With each of the key target markets representing multi-billion-dollar opportunities, Nuvilex offers investors multiple opportunities for success and should trade at a valuation that reflects its current development progress to date.

The company primarily focuses on the advancement of its treatment for advanced, inoperable pancreatic cancer that combines the Cell-in-a-Box technology with the anti-cancer drug ifosfamide. This treatment has completed Phase 1/2 clinical trials. The company, through its subsidiary, Medical Marijuana Sciences, Inc., uses constituents of Cannabis in developing treatments for cancer, particularly those that are difficult to treat

.

With the excitement and buzz circulating around this stock in the last few months there is a lot of speculation as to the validity of NVLX. To help investors get a better grasp on NVLX, we have decided to offer a comprehensive research report below.

This comprehensive research report is authored by a Chartered Financial Analyst and includes vital information that every shareholder of NVLX must read. There is no charge for this report. Included in the report you will find recent highlights of NVLX, Overview of the Global Pharmaceuticals Industry, U.S Food and Drug Administration's (FDA) Approval process for NVLX products, in-depth description of company history, pipeline drugs and current stage, financial position, valuation of company, analyst summary, and price target: http://bit.ly/NVLX-PriceTarget copy and paste may be required